Sign In
Buy AKTX
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update
02:28am, Tuesday, 17'th Mar 2026
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the target of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 209,369 shares, a
Highlights strategic progress achieved under Abizer Gaslightwala's leadership, including advancement of AKTX-101 and expansion of Akari's ADC pipeline
Akari Therapeutics (NASDAQ:AKTX) Stock Passes Above 50-Day Moving Average – Here’s Why
04:18am, Wednesday, 11'th Mar 2026
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.26 and traded as hi
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
09:10am, Thursday, 26'th Feb 2026
TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncolog
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
09:05am, Wednesday, 18'th Feb 2026
TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncolog
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
02:14pm, Wednesday, 11'th Feb 2026
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline
08:45am, Wednesday, 11'th Feb 2026
CEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
09:15am, Thursday, 05'th Feb 2026
– Live video webcast on Tuesday, February 10 th at 1:00 PM EST
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Drops By 51.1%
01:22am, Friday, 30'th Jan 2026
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 211,849 shares, a drop of 51.1
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
08:45am, Monday, 26'th Jan 2026
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct t
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
09:00am, Friday, 09'th Jan 2026
Access the Akari CEO Corner here
Akari Therapeutics to Present at the 2026 Biotech Showcase
09:15am, Thursday, 08'th Jan 2026
In-person presentation on Tuesday, January 13 th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones f
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
09:15am, Tuesday, 30'th Dec 2025
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
08:30am, Tuesday, 23'rd Dec 2025
Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
08:30am, Thursday, 18'th Dec 2025
Watch the “What This Means” video here
